ReviewFrontiers in cellular and infection microbiology2022
Vaccines against candidiasis: Status, challenges and emerging opportunity.
Review in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Molecular and regulatory aspects of EPA: a Nakaseomyces glabratus epithelial adhesin.Archives of microbiology · 2026Review
- Characterization of dual DNA polymerase knockout strains of Candida albicans with live whole-cell vaccine competence.NPJ vaccines · 2025Article
- The evaluation of a novel multi-epitope vaccine against human papillomavirus and Candida albicans.Journal, genetic engineering & biotechnology · 2025Article
- Candida albicans: the current status regarding vaginal infections.Applied microbiology and biotechnology · 2025Review
- Identification of chicken-derived antibodies targeting the Candida albicans Als3 protein.Applied microbiology and biotechnology · 2025Article
- Access to Substituted Tricyclic Heteroarenes by an Oxidative Cyclization Reaction and Their Antifungal Performance.Pharmaceuticals (Basel, Switzerland) · 2025Article
- New antifungal strategies and drug development against WHO critical priority fungal pathogens.Frontiers in cellular and infection microbiology · 2025Review
- Dual-antigen fusion protein vaccination induces protective immunity againstHuman vaccines & immunotherapeutics · 2024Article
- From High Protection to Lethal Effect: Diverse Outcomes of Immunization Against Invasive Candidiasis with DifferentInternational journal of molecular sciences · 2024Article
- Toll-like receptor 4 (TLR4) is the major pattern recognition receptor triggering the protective effect of amSphere · 2024Article
- Immunogenicity and efficacy of CNA25 as a potential whole-cell vaccine against systemic candidiasis.EMBO molecular medicine · 2024Article
- A chemically induced attenuated strain ofeLife · 2024Article
- Invasive candidiasis.Nature reviews. Disease primers · 2024Review
- Hsp90-Mediated Multi-Drug Resistance in DNA Polymerase-Defective Strains ofJournal of fungi (Basel, Switzerland) · 2024Article
- Article
- Advancing Vaccine Strategies againstVaccines · 2023Review
- Molecular Cloning, Heterologous Expression, Purification, and Evaluation of Protein-Ligand Interactions of CYP51 ofBiomedicines · 2023Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candidiasis is a mycosis caused by opportunistic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.